Capsulution and EBARA Expand Co-operation
Pre-Clinical Studies in the Focus of Product Development
EBARA Corp. and Capsulution NanoScience AG recently finalised the expansion of their co-operation that began in 2005. As such, the two companies are now also collaborating to develop new products for the improved and goal-oriented delivery of pharmaceutical substances.
In order to achieve this goal, the two companies have selected concrete active agents whose delivery properties are to be improved using Capsulution's nanocapsules or complexes. At the foreground of development is the time-controlled release of the active agents. In particular, products are to be adapted especially to the needs of the Japanese pharmaceutical market. Presently the new active agent formulas are to undergo testing to determine their effects on living organisms in the context of pre-clinical experiments in Japan. The costs for further development are divided equally between the two companies.
Other news from the department business & finance
